Profile data is unavailable for this security.
About the company
RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in HKD (TTM)2.34bn
- Net income in HKD-1.29bn
- Incorporated2008
- Employees3.07k
- LocationRemeGen Co LtdNo.1 Rongchang Road, Yantai ETDZYANTAI 264006ChinaCHN
- Phone+86 5 353573685
- Fax+86 5 356113517
- Websitehttps://www.remegen.cn/
More ▼
18.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 18 Jun 2024 | 9.16m | 4.39% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 6.91m | 3.32% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 4.01m | 1.92% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.54m | 1.70% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2025 | 3.39m | 1.62% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 3.30m | 1.58% |
| Allianz Global Investors Asia Pacific Ltd.as of 30 Dec 2025 | 2.92m | 1.40% |
| Yongying Asset Management Co., Ltd.as of 30 Jun 2025 | 1.66m | 0.80% |
| BlackRock Advisors (UK) Ltd.as of 09 Jan 2026 | 1.61m | 0.77% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 1.41m | 0.67% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
